Cargando…

An Elaborate New Linker System Significantly Enhances the Efficacy of an HER2‐Antibody‐Drug Conjugate against Refractory HER2‐Positive Cancers

Human epidermal growth factor receptor 2 (HER2) is overexpressed in breast and gastric cancers and this causes poor clinical outcomes. Although both T‐DM1 and Enhertu are approved as an HER2‐targeting antibody‐drug conjugate (ADC), the effects of these drugs are still not satisfactory to eradicate d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shin, Seol Hwa, Park, Yun‐Hee, Park, Seok Soon, Ju, Eun Jin, Park, Jin, Ko, Eun Jung, Bae, Dong Jun, Kim, Sang‐Yeob, Chung, Chul‐Woong, Song, Ho Young, Jang, Se Jin, Jeong, Seong‐Yun, Song, Si Yeol, Choi, Eun Kyung
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8655175/ https://www.ncbi.nlm.nih.gov/pubmed/34664433 http://dx.doi.org/10.1002/advs.202102414

Ejemplares similares

Predictive biological factors for late survival in patients with HER2-positive breast cancer
por: Kang, Young-Joon, et al.
Publicado: (2023)

Therapeutic Application of Drug-Conjugated HER2 Oligobody (HER2-DOligobody)
por: Kim, Hyun Jung, et al.
Publicado: (2020)

Determining the Factors Predicting the Response to Anti-HER2 Therapy in HER2-Positive Breast Cancer Patients
por: You, Ji Young, et al.
Publicado: (2023)

Serial Serum HER2 Measurements for the Detection of Breast Cancer Recurrence in HER2-Positive Patients
por: Ha, June-Hyung, et al.
Publicado: (2014)

Overexpression of HER2/HER3 and clinical feature of ovarian cancer
por: Chung, Ye Won, et al.
Publicado: (2019)

Doxorubicin conjugated with a trastuzumab epitope and an MMP-2 sensitive peptide linker for the treatment of HER2-positive breast cancer
por: You, Yiwen, et al.
Publicado: (2018)

Role of HER2 mutations in refractory metastatic breast cancers: targeted sequencing results in patients with refractory breast cancer
por: Park, Yeon Hee, et al.
Publicado: (2015)

Breast cancer stem cells in HER2-negative breast cancer cells contribute to HER2-mediated radioresistance and molecular subtype conversion: clinical implications for serum HER2 in recurrent HER2-negative breast cancer
por: Kim, Yun Gyoung, et al.
Publicado: (2017)

Integrative In Vivo Drug Testing Using Gene Expression Signature and Patient-Derived Xenografts from Treatment-Refractory HER2 Positive and Triple-Negative Subtypes of Breast Cancer
por: Ryu, Jin-Sun, et al.
Publicado: (2019)

Effect of Inter-Domain Linker Composition on Biodistribution of ABD-Fused Affibody-Drug Conjugates Targeting HER2
por: Xu, Tianqi, et al.
Publicado: (2022)

HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates
por: Ocaña, Alberto, et al.
Publicado: (2020)

BioPATH: A Biomarker Study in Asian Patients with HER2+ Advanced Breast Cancer Treated with Lapatinib and Other Anti-HER2 Therapy
por: Kim, Sung-Bae, et al.
Publicado: (2019)

Single-molecule functional anatomy of endogenous HER2-HER3 heterodimers
por: Choi, Byoungsan, et al.
Publicado: (2020)

Development of HER2-Specific Aptamer-Drug Conjugate for Breast Cancer Therapy
por: Jeong, Hwa Yeon, et al.
Publicado: (2020)

Prognostic Significance of HER2 Gene Amplification According to Stage of Breast Cancer
por: Kim, Yong-Seok, et al.
Publicado: (2008)

Irreversible HER2 inhibitors overcome resistance to the RSL3 ferroptosis inducer in non-HER2 amplified luminal breast cancer
por: Park, Soon Young, et al.
Publicado: (2023)

A chemical conjugate between HER2-targeting antibody fragment and Pseudomonas exotoxin A fragment demonstrates cytotoxic effects on HER2-expressing breast cancer cells
por: Lee, Sunju, et al.
Publicado: (2019)

ITC-6102RO, a novel B7-H3 antibody-drug conjugate, exhibits potent therapeutic effects against B7-H3 expressing solid tumors
por: Shin, Seol Hwa, et al.
Publicado: (2023)

Differences in clinical outcomes between HER2-negative and HER2-positive luminal B breast cancer
por: Kang, Byeongju, et al.
Publicado: (2023)

The Significance of Serum HER2 Levels at Diagnosis on Intrinsic Subtype-Specific Outcome of Operable Breast Cancer Patients
por: Lee, Moo Hyun, et al.
Publicado: (2016)

PTEN loss and level of HER2 amplification is associated with trastuzumab resistance and prognosis in HER2-positive gastric cancer
por: Kim, Chan, et al.
Publicado: (2017)

Cardiotoxicity of trastuzumab in patients with HER2-positive gastric cancer
por: Soo Park, Ji, et al.
Publicado: (2017)

Gene expression assay and Watson for Oncology for optimization of treatment in ER-positive, HER2-negative breast cancer
por: Kim, Yun Yeong, et al.
Publicado: (2018)

Perioperative HER2 targeted treatment in early stage HER2-positive breast cancer
por: Hong, Joohyun, et al.
Publicado: (2022)

Genomic analysis of plasma circulating tumor DNA in patients with heavily pretreated HER2 + metastatic breast cancer
por: Lee, Kyoungmin, et al.
Publicado: (2023)

HER3 targeting with an antibody‐drug conjugate bypasses resistance to anti‐HER2 therapies
por: Gandullo‐Sánchez, Lucía, et al.
Publicado: (2020)

Clinicopathologic characteristics of HER2-positive pure mucinous carcinoma of the breast
por: Jang, Yunjeong, et al.
Publicado: (2020)

HER2 as a novel therapeutic target for cervical cancer
por: Oh, Doo-Yi, et al.
Publicado: (2015)

HER2 amplification by next-generation sequencing to identify HER2-positive invasive breast cancer with negative HER2 immunohistochemistry
por: Morsberger, Laura, et al.
Publicado: (2022)

Advances in Antibody-Drug Conjugates in the Treatment of HER2-Positive Breast Cancer
por: Yu, Yongchao, et al.
Publicado: (2022)

A Retrospective Analysis for Patients with HER2-Positive Gastric Cancer Who Were Treated with Trastuzumab-Based Chemotherapy: In the Perspectives of Ethnicity and Histology
por: Yi, Jun Ho, et al.
Publicado: (2016)

Polyethylene glycol-conjugated HER2-targeted peptides as a nuclear imaging probe for HER2-overexpressed gastric cancer detection in vivo
por: Guan, Siao-Syun, et al.
Publicado: (2018)

Targeting phosphomevalonate kinase enhances radiosensitivity via ubiquitination of the replication protein A1 in lung cancer cells
por: Park, Seok Soon, et al.
Publicado: (2023)

Therapeutic implication of HER2 in advanced biliary tract cancer
por: Nam, Ah-Rong, et al.
Publicado: (2016)

Significance of HER2 protein expression and HER2 gene amplification in colorectal adenocarcinomas
por: Wang, Xin-Yu, et al.
Publicado: (2019)

Correlation of HER2, p95HER2 and HER3 Expression and Treatment Outcome of Lapatinib plus Capecitabine in her2-Positive Metastatic Breast Cancer
por: Han, Sae-Won, et al.
Publicado: (2012)

Low PR in ER(+)/HER2(−) breast cancer: high rates of TP53 mutation and high SUV
por: Ahn, Sung Gwe, et al.
Publicado: (2018)

A Conjugate Based on Anti-HER2 Diaffibody and Auristatin E Targets HER2-Positive Cancer Cells
por: Serwotka-Suszczak, Anna M., et al.
Publicado: (2017)

Novel HER2 Aptamer Selectively Delivers Cytotoxic Drug to HER2-positive Breast Cancer Cells in Vitro
por: Liu, Zhe, et al.
Publicado: (2012)

Association between tumor (18)F-fluorodeoxyglucose metabolism and survival in women with estrogen receptor-positive, HER2-negative breast cancer
por: Chae, Sun Young, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_s4qcv2k4op4dgus9u5979ujur8